Optical Coherence Tomography in Patients With Radiotherapy for Head and Neck Cancer (ROOCT)

February 28, 2026 updated by: Hans Geinitz, Krankenhaus Barmherzige Schwestern Linz

Live Laser Microscopic Evaluation (OCT) of Radiation Induced Preclinical Alterations of the Skin in Head and Neck Cancer Patients

The purpose of this study is to determine whether any eventual skin damage caused by radiation therapy can be detected and monitored at a subclinical level via optical coherence tomography (OCT). Another key question is whether subclinical OCT detected skin damage correlates with acute and late clinical toxicity.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Head and neck cancer patients that meet the eligibility criteria and singned the informed consent will undergo OCT-measurements before, during and after the course of radiation therapy. At the same time-points the skin areas are evaluated with dermatoscopy and patients are asked to self-assess their quality of life (EORTC QLQ C30 and respective head and neck module H&N 43).

Study Type

Observational

Enrollment (Actual)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Upper Austria
      • Linz, Upper Austria, Austria, 4010
        • Department of Radiooncology, Ordensklinikum Linz GmbH Barmherzige Schwestern

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Consecutively treated patients with head and neck cancer at the department of radiation therapy Ordensklinikum Linz Barmherzige Schwestern

Description

Inclusion Criteria:

  • Patients with cancer located at: nasopharynx, oropharynx, hypopharynx, larynx, oral cavity and definitive or adjuvant radiation- or radio-chemotherapy

Exclusion Criteria:

  • reduced mental capacity
  • treatment with C225 Cetuximab
  • bearded patients
  • overt skin disease
  • vast tattoos in the neck region

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Head and Neck Cancer Patients
Patients with adjuvant or definitve radiotherapy or radio-chemotherapy for head and neck cancer
3x3 OCT volume scans on treated and opposite side of the irreadiated area on head and neck
Other Names:
  • Lumedica OQlabscope 2.0
2x2 pictures taken with a dermatoscope
Other Names:
  • Heine iC1 Set/6

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
early radiation induced skin structure changes detected in OCT
Time Frame: First week of radiation therapy
any reproducible difference in skin OCT appearance as compared with baseline (pre-RT)
First week of radiation therapy

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
detection of any skin strucure changes with OCT during the course of RT
Time Frame: weeks 1 - 6 of radiation therapy
any reproducible difference in skin OCT appearance as compared with baseline (pre-RT)
weeks 1 - 6 of radiation therapy
Correlation of OCT changes with clinical appearent acute side effetcs
Time Frame: weeks 1 - 6 of radiation therapy
Correlation of OCT changes with CTC radiation toxicity
weeks 1 - 6 of radiation therapy
Correlation of OCT changes with clinical appearent late side effetcs
Time Frame: 1 year post-RT
Correlation of OCT changes with CTC radiation toxicity
1 year post-RT
Correlation of OCT changes with radiation sensitivity
Time Frame: OCT: weeks 1-6 of radiation therapy; FISH: pre-RT
Correlation of OCT with chromosome-breaks per metaphasis in in-vitro irradiated blood lymphocytes (FISH)
OCT: weeks 1-6 of radiation therapy; FISH: pre-RT
Correlation of OCT changes with dermatoscopic skin appearance
Time Frame: weeks 1-6 of RT
Correlation of OCT changes with standardised evaluated skin appearence via dermatoscopy
weeks 1-6 of RT
Correlation of quality of live with OCT and radiation sensitivity
Time Frame: weeks 1-6 of RT, 6 weeks and 1 year post-RT
Correlation of quality of live as measured with the EORT QLC C30 and Head and neck module H&N 43 with OCT and radiation sensitivity
weeks 1-6 of RT, 6 weeks and 1 year post-RT

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Hans Geinitz, Prim. Univ.-Prof. Dr., Ordensklinikum Linz GmbH Barmherzige Schwestern (Dept. Radiooncology)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 8, 2020

Primary Completion (Actual)

December 8, 2024

Study Completion (Actual)

April 8, 2025

Study Registration Dates

First Submitted

October 29, 2020

First Submitted That Met QC Criteria

October 29, 2020

First Posted (Actual)

October 30, 2020

Study Record Updates

Last Update Posted (Actual)

March 3, 2026

Last Update Submitted That Met QC Criteria

February 28, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Head and Neck Cancer

Clinical Trials on OCT

Subscribe